Please ensure Javascript is enabled for purposes of website accessibility

Novavax Makes a $167 Million Purchase to Boost Its Coronavirus Vaccine Production Capacity

By Cory Renauer – May 27, 2020 at 3:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After acquiring a Czech company, the clinical-stage biotech will be able to churn out more than 1 billion doses of its SARS-CoV-2 vaccine candidate next year -- if it works.

A small-cap biotech is joining its large-cap peers by heavily boosting its manufacturing capacity for an experimental coronavirus vaccine long before finding out whether that vaccine is effective. On Wednesday, Novavax (NVAX -5.30%) announced it's acquiring Praha Vaccines and its biologics factory in Bohumil, Czech Republic, for $167 million in cash.

The assets changing hands include a 150,000-square-foot vaccine-and-biologics manufacturing facility and support buildings. And Novavax will retain Praha's existing employees to keep the whole operation functioning. 

Coronavirus vaccine hause

Image source: Getty Images.

Increasing capacity 

With the addition of those new assets, Novavax estimates that it will be able to produce more than 1 billion doses of its SARS-CoV-2 vaccine candidate, NVX-CoV2373, in 2021.

While this might seem like an awfully risky step for a clinical-stage drugmaker that has no products to sell yet, it could help Novavax forge a lucrative relationship with a major player in the vaccine market. Previously, Praha Vaccines was a part of Cyrus Poonawalla Group, which also owns the Serum Institute of India (SII). SII produces more than 1.3 billion doses of vaccines annually for diseases such as polio, diphtheria, tetanus, making it the world's leading vaccine producer by volume.

On Monday, Novavax began dosing the people enrolled in its phase 1 trial with NVX-CoV2373. The company expects to have preliminary results from this study in July. While there aren't enough patients enrolled to provide solid evidence about whether or not NVX-CoV2373 effectively prevents COVID-19 infections, the data could show whether or not it safely coaxes the immune system to produce antibodies to SARS-CoV-2.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$18.57 (-5.30%) $-1.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.